- Home
- CANF vs MODV Comparison
CANF vs MODV Comparison
Compare CANF & MODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MODV
- Stock Information
- Founded
- CANF 1994
- MODV 1996
- Country
- CANF Israel
- MODV United States
- Employees
- CANF N/A
- MODV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MODV Transportation Services
- Sector
- CANF Health Care
- MODV Consumer Discretionary
- Exchange
- CANF Nasdaq
- MODV Nasdaq
- Market Cap
- CANF 14.8M
- MODV 16.1M
- IPO Year
- CANF N/A
- MODV N/A
- Fundamental
- Price
- CANF $1.10
- MODV $3.95
- Analyst Decision
- CANF Strong Buy
- MODV Buy
- Analyst Count
- CANF 2
- MODV 4
- Target Price
- CANF $14.00
- MODV $9.17
- AVG Volume (30 Days)
- CANF 68.3K
- MODV 12.8M
- Earning Date
- CANF 06-17-2025
- MODV 05-08-2025
- Dividend Yield
- CANF N/A
- MODV N/A
- EPS Growth
- CANF N/A
- MODV N/A
- EPS
- CANF N/A
- MODV N/A
- Revenue
- CANF $674,000.00
- MODV $2,753,789,000.00
- Revenue This Year
- CANF $461.72
- MODV N/A
- Revenue Next Year
- CANF N/A
- MODV $5.20
- P/E Ratio
- CANF N/A
- MODV N/A
- Revenue Growth
- CANF N/A
- MODV N/A
- 52 Week Low
- CANF $0.98
- MODV $0.87
- 52 Week High
- CANF $4.69
- MODV $32.82
- Technical
- Relative Strength Index (RSI)
- CANF 46.91
- MODV 77.55
- Support Level
- CANF $1.07
- MODV $1.07
- Resistance Level
- CANF $1.12
- MODV $3.48
- Average True Range (ATR)
- CANF 0.03
- MODV 0.63
- MACD
- CANF 0.02
- MODV 0.35
- Stochastic Oscillator
- CANF 75.00
- MODV 81.48
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MODV ModivCare Inc.
ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. Its solutions address the social determinants of health (SDoH) by connecting members to essential care services. Its various service offerings include non-emergency medical transportation, personal care, virtual and remote monitoring, consumer health engagement, and integrated supportive care. The company's reportable segments are NEMT, PCS, Monitoring, and Corporate and Other. A majority of its revenue is generated from the NEMT segment, which provides non-emergency medical transportation services.